Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey

Duan, Jia Yu; Duan, Guang Cai; Wang, Chong Jian; Liu, Dong Wei; Qiao, Ying; Pan, Shaokang; Jiang, Deng Ke; Liu, Yong; Zhao, Zi Hao; Liang, Lu Lu; Tian, Fei; Liu, Zhang Suo

doi:10.1186/s12882-020-01761-5

Cited by 46 publications

(43 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 14 , 15 Indeed, while only 1.6% of our COVID-19 patients had a previous history of chronic kidney diseases, 30.8% had a history of DM and 30.4% had a history of hypertension, in which both were considered major risk factors for the development of chronic kidney disease and reduced eGFR. 16 …”

Section: Discussionmentioning

confidence: 99%

Kidney Dysfunction among COVID-19 Patients in the United Arab Emirates

Hachim

Naeem

et al. 2021

Oman Med J

View full text Add to dashboard Cite

Objectives: We sought to determine the estimated glomerular filtration rate (eGFR) among patients with COVID-19 and to examine its correlation with different demographic, clinical, and laboratory characteristics. Methods: This study examined patients diagnosed with COVID-19 and enrolled at Al Kuwait Hospital, Dubai, UAE. eGFR was calculated using the Modification of Diet in Renal Disease equation, 186 × (SCr mg/dL)-1.154 × (age)-0203 × 0.742 [if female] × 1.212 [if black], and compared for 250 COVID-19 cases and 153 non-COVID-19 controls. Analysis were performed using univariate statistics. Results: The overall mean age of the cohort was 47.2±14.0 years, and 54.6% (n = 220) were males. The results showed that 45.3% of COVID-19 patients had mild-severe renal impairment, as reflected in the eGFR. When compared to patients with normal eGFR, those with severe renal impairment were older (62.5 vs. 40.2 years; p < 0.001), more likely to be male (100% vs. 71.1%; p = 0.016), and have comorbidities (90.9% vs. 40.0%; p < 0.001) including diabetes mellitus (72.7% vs. 21.5%; p < 0.001) and hypertension (72.7% vs. 25.2%; p = 0.003). They were also more likely to be associated with those that had severe (36.4% vs. 25.9%; p < 0.001) and critical (63.6% vs. 16.3%; p < 0.001) COVID-19 infection as well as intensive care unit admission (72.7% vs. 16.3%; p < 0.001). Correlational analysis showed a significant association between renal function indicators and different laboratory markers, including hematological indices and different liver enzymes. Conclusions: This is the first study to examine the renal function among COVID-19 cases in the Middle East. Nearly half of COVID-19 patients had moderate to severe renal impairment. Diabetes mellitus and hypertension were the most common underlying comorbidities associated with moderate-severe renal function impairment among COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Kidney Dysfunction among COVID-19 Patients in the United Arab Emirates

Hachim

Naeem

et al. 2021

Oman Med J

View full text Add to dashboard Cite

show abstract

“…Additionally, when uric acid is present in the cytoplasm of cells or in the acidic/hydrophobic environment of atherosclerotic plaques, it is converted to a pro-oxidant, and it promotes oxidative stress, including cardiovascular disease through this mechanism, participating in the pathophysiology of human disease [21]. Recent studies reported that hyperuricemia is an independent predictor of CKD [22,23]. Uric acid concentration is an independent risk factor for kidney failure in earlier stages of CKD and has a J-shaped relationship with all-cause mortality in CKD [24].…”

Section: Discussionmentioning

confidence: 99%

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study

Akahane

Namisaki

et al. 2020

JCM

View full text Add to dashboard Cite

It is unclear whether the link between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) is mediated by common risk factors. We aimed to elucidate the association between NAFLD and CKD using propensity score (PS)-matched analysis. We assessed 3725 Japanese individuals, excluding those with hepatitis B or C infection and men and women who consumed >30 and >20 g/day of alcohol, respectively. Of these, we enrolled 1097 Japanese subjects with NAFLD diagnosed by ultrasonography and 1097 PS-matched subjects without NAFLD. The prevalence of CKD was higher in subjects with NAFLD than in those without NAFLD before PS matching, but there was no significant difference between these groups in terms of CKD prevalence after PS matching. There was no difference in the prevalence of CKD between those with and without NAFLD in the subgroup analyses. Logistic regression analysis demonstrated that obesity, hypertension, and hyperuricemia were independent predictors of CKD, but NAFLD was not independently associated with CKD. In subjects with NAFLD, obesity, hypertension, and hyperuricemia were independent predictors of CKD. Thus, the link between NAFLD and CKD may be mediated by common risk factors. We recommend screening for CKD when patients with NAFLD have the aforementioned comorbidities.

show abstract

“…При этом отмечаются определенные различия в распространенности в разных частях мира. По обобщенным результатам 19 популяционных исследований из 13 европейских стран скорректированная распространенность ХБП 1-5 стадий варьировала от 3,31% (3,30-3,33%) в Норвегии до 17,3% (16,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18),1%) в северо-восточной Германии, скорректированная распространенность ХБП 3-5 стадий варьировала от 1,0% (0,7-1,3%) в центральной Италии до 5,9% (5,2-6,6%) в северо-восточной Германии [5]. Распространенность ХБП С1-5 в Восточной Африке составляет 6,8% (5,7-8,1%) и варьирует по регионам: 12,5% (10,1-15,4%) в восточной части Уганды, 3,9% (2,2-6,8%) на юго-западе Уганды и 3,7% (2,7-5,1%) в западной Кении [6].…”

Section: распространенность хронической болезни почекunclassified

“…Распространенность ХБП С1-5 в Восточной Африке составляет 6,8% (5,7-8,1%) и варьирует по регионам: 12,5% (10,1-15,4%) в восточной части Уганды, 3,9% (2,2-6,8%) на юго-западе Уганды и 3,7% (2,7-5,1%) в западной Кении [6]. Распространенность ХБП С1-5 в центральном Китае составляет 16,8% (15,8-17,8%) [7]. В Российской Федерации (РФ) по результатам московского исследования распространенность ХБП С1-5 составила 4% общей популяции, из которых 4,8% были пациентами с ХБП С4-5 [8].…”

Section: распространенность хронической болезни почекunclassified

Chronic Kidney Disease: Current State of the Problem

Батюшин

2020

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is characterized by increasing prevalence, catalyzing properties in relation to cardiovascular and general mortality, and, in most cases, is asymptomatic, which means late diagnostic verifiability. The global average prevalence of CKD is 13.4%, and CKD C3-5 is 10.6%. The main causes of CKD C5 are diabetes mellitus (DM, 46.9%), hypertension (28.8%) and to a lesser extent, glomerulonephritis (7.1%) and polycystic diseases (2.8%), while other causes account for a total of 14.4%. Despite the simple diagnosis of CKD, one of the key problems of modern therapeutic and pediatric clinics is its low detection rate at the early stages, which, according to some data, reaches 96.6%. This review provides data on the criteria for the diagnosis of CKD, as well as more detailed consideration of the course of CKD in patients with DM, hypertension, and heart failure. Attention is paid to the medicinal origin of CKD, as well as to the development of anxiety and depressive disorders in CKD. General issues of treatment of patients with CKD are considered in detail. Lifestyle changes are an important part of the fight against the development and progression of CKD. Currently, Smoking, alcohol, and physical inactivity have been shown to have a harmful effect on the risk of developing and progressing CKD. Diet plays a certain preventive role. The main drugs with nephroprotective properties are angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Both classes of drugs are effective in proteinuric forms of nephropathies and in combination/association of CKD with diabetes or hypertension. The review also provides data on the nephroprotective properties of mineralocorticoid receptor antagonists, endothelin receptor antagonists, and sodium-glucose co-transporter-2 inhibitors. Given the high importance of identifying and effectively treating patients with CKD, it is necessary to focus on early detection of CKD, especially in high-risk groups. It is necessary to raise public awareness by creating and implementing programs for primary prevention of CKD, as well as awareness of patients, motivating them to follow the doctor's recommendations for a long time, including as part of the implementation of a non-drug strategy to combat CKD. It is important to use the full range of methods of drug therapy for CKD, including measures of universal nephroprotection. It should be remembered that the cost of late diagnosis of CKD is a reduction in life expectancy, primarily due to high rates of cardiovascular mortality, disability, and high-cost medication and kidney replacement therapy.

show abstract

Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey

Cited by 46 publications

References 50 publications

Kidney Dysfunction among COVID-19 Patients in the United Arab Emirates

Kidney Dysfunction among COVID-19 Patients in the United Arab Emirates

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study

Chronic Kidney Disease: Current State of the Problem

Contact Info

Product

Resources

About